Physician profile
Jacqi I Lambert
NPI 1467407569
$8,513.29
in general payments reported to CMS, 2019-2025
41 companies · $1,730 in 2025
The $1,730 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $917 · 2021: $1,049 · 2022: $1,107 · 2023: $1,187 · 2024: $1,673 · 2025: $1,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,589.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,294.23 | 2019-2025 | |
| Abbvie INC. | $1,041.23 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $936.63 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $842.92 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $792.07 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $562.25 | 2019-2025 | Evenity, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.54 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.54 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $223.40 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Allergan, INC. | $202.99 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.31 | 2019-2022 | |
| Amarin Pharma, INC. | $177.19 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $165.05 | 2019-2025 | |
| Abbott Laboratories | $159.95 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $153.47 | 2019-2025 | M-M-R II, Gardasil 9, Capvaxive |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $124.06 | 2019-2025 | Spravato, Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $116.58 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $88.15 | 2019-2022 | |
| Astellas Pharma US INC | $80.51 | 2019-2025 | Veozah |
| Sumitomo Pharma America, INC. | $67.81 | 2024-2025 | Gemtesa |
| Dexcom, INC. | $62.99 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Eisai INC. | $58.49 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $50.90 | 2021-2022 | |
| Exact Sciences Corporation | $49.87 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Organon LLC | $45.35 | 2022-2023 | Nexplanon |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.98 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $36.89 | 2019 | |
| Sanofi Pasteur INC. | $36.80 | 2020-2023 | |
| Corcept Therapeutics | $34.11 | 2024-2025 | Korlym |
| Grifols USA, LLC | $31.77 | 2019-2021 | |
| Biogen, INC. | $24.61 | 2022 | |
| Radius Health, INC. | $24.23 | 2021-2022 | |
| Axsome Therapeutics, INC. | $23.88 | 2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $19.00 | 2025 | Fanapt |
| Antares Pharma, INC. | $18.01 | 2025 | Xyosted |
| Averitas Pharma INC. | $17.01 | 2023 | Qutenza |
| Esperion Therapeutics, INC. | $16.23 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.13 | 2024 | Quviviq |
| Nalpropion Pharmaceuticals LLC | $14.24 | 2019 | |
| Shire North American Group INC | $13.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqi Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.